M1 KLINIKEN AG (M12.DE) Fundamental Analysis & Valuation

FRA:M12 • DE000A0STSQ8

Current stock price

14.66 EUR
+0.12 (+0.83%)
Last:

This M12.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. M12.DE Profitability Analysis

1.1 Basic Checks

  • In the past year M12 was profitable.
  • In the past year M12 had a positive cash flow from operations.
  • Each year in the past 5 years M12 has been profitable.
  • M12 had a positive operating cash flow in each of the past 5 years.
M12.DE Yearly Net Income VS EBIT VS OCF VS FCFM12.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

1.2 Ratios

  • The Return On Assets of M12 (8.73%) is better than 96.30% of its industry peers.
  • M12 has a better Return On Equity (15.03%) than 92.59% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 13.44%, M12 belongs to the top of the industry, outperforming 96.30% of the companies in the same industry.
  • M12 had an Average Return On Invested Capital over the past 3 years of 7.72%. This is in line with the industry average of 5.91%.
  • The 3 year average ROIC (7.72%) for M12 is below the current ROIC(13.44%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.73%
ROE 15.03%
ROIC 13.44%
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
M12.DE Yearly ROA, ROE, ROICM12.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • M12's Profit Margin of 5.00% is amongst the best of the industry. M12 outperforms 88.89% of its industry peers.
  • M12's Profit Margin has declined in the last couple of years.
  • The Operating Margin of M12 (8.52%) is better than 74.07% of its industry peers.
  • M12's Operating Margin has declined in the last couple of years.
  • M12's Gross Margin of 19.29% is in line compared to the rest of the industry. M12 outperforms 44.44% of its industry peers.
  • In the last couple of years the Gross Margin of M12 has declined.
Industry RankSector Rank
OM 8.52%
PM (TTM) 5%
GM 19.29%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
M12.DE Yearly Profit, Operating, Gross MarginsM12.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. M12.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), M12 is creating value.
  • Compared to 1 year ago, M12 has less shares outstanding
  • Compared to 5 years ago, M12 has more shares outstanding
  • Compared to 1 year ago, M12 has a worse debt to assets ratio.
M12.DE Yearly Shares OutstandingM12.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
M12.DE Yearly Total Debt VS Total AssetsM12.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • M12 has an Altman-Z score of 5.25. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
  • M12 has a better Altman-Z score (5.25) than 96.30% of its industry peers.
  • The Debt to FCF ratio of M12 is 0.70, which is an excellent value as it means it would take M12, only 0.70 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of M12 (0.70) is better than 100.00% of its industry peers.
  • M12 has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • M12's Debt to Equity ratio of 0.05 is amongst the best of the industry. M12 outperforms 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.7
Altman-Z 5.25
ROIC/WACC1.83
WACC7.33%
M12.DE Yearly LT Debt VS Equity VS FCFM12.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 2.06 indicates that M12 has no problem at all paying its short term obligations.
  • M12's Current ratio of 2.06 is amongst the best of the industry. M12 outperforms 88.89% of its industry peers.
  • A Quick Ratio of 1.35 indicates that M12 should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.35, M12 belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 1.35
M12.DE Yearly Current Assets VS Current LiabilitesM12.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. M12.DE Growth Analysis

3.1 Past

  • M12 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.36%, which is quite good.
  • Measured over the past 5 years, M12 shows a small growth in Earnings Per Share. The EPS has been growing by 7.97% on average per year.
  • M12 shows a small growth in Revenue. In the last year, the Revenue has grown by 6.52%.
  • The Revenue has been growing by 34.44% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.27% on average over the next years. This is quite good.
  • M12 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.24% yearly.
EPS Next Y9.46%
EPS Next 2Y12.44%
EPS Next 3Y12.27%
EPS Next 5YN/A
Revenue Next Year5.17%
Revenue Next 2Y6.28%
Revenue Next 3Y6.07%
Revenue Next 5Y8.24%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
M12.DE Yearly Revenue VS EstimatesM12.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
M12.DE Yearly EPS VS EstimatesM12.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. M12.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.60 indicates a correct valuation of M12.
  • Compared to the rest of the industry, the Price/Earnings ratio of M12 indicates a somewhat cheap valuation: M12 is cheaper than 62.96% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.50. M12 is valued slightly cheaper when compared to this.
  • A Price/Forward Earnings ratio of 13.17 indicates a correct valuation of M12.
  • M12's Price/Forward Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.67, M12 is valued a bit cheaper.
Industry RankSector Rank
PE 15.6
Fwd PE 13.17
M12.DE Price Earnings VS Forward Price EarningsM12.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • M12's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. M12 is cheaper than 62.96% of the companies in the same industry.
  • M12's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 10.78
EV/EBITDA 7.01
M12.DE Per share dataM12.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of M12 may justify a higher PE ratio.
  • M12's earnings are expected to grow with 12.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.65
PEG (5Y)1.96
EPS Next 2Y12.44%
EPS Next 3Y12.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. M12.DE Dividend Analysis

5.1 Amount

  • M12 has a Yearly Dividend Yield of 3.44%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 1.96, M12 pays a better dividend. On top of this M12 pays more dividend than 81.48% of the companies listed in the same industry.
  • M12's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 3.44%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
M12.DE Yearly Dividends per shareM12.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2024 2025 0.1 0.2 0.3 0.4

5.3 Sustainability

DPN/A
EPS Next 2Y12.44%
EPS Next 3Y12.27%
M12.DE Yearly Income VS Free CF VS DividendM12.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

More info and screens

Find the best dividend stocksShow peers with best dividend

M12.DE Fundamentals: All Metrics, Ratios and Statistics

M1 KLINIKEN AG

FRA:M12 (3/23/2026, 7:00:00 PM)

14.66

+0.12 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-18
Earnings (Next)04-16
Inst Owners0.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap287.92M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85.71
Price Target28.05 (91.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.44%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)4.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE 15.6
Fwd PE 13.17
P/S 0.81
P/FCF 10.78
P/OCF 10.65
P/B 2.44
P/tB 10.48
EV/EBITDA 7.01
EPS(TTM)0.94
EY6.41%
EPS(NY)1.11
Fwd EY7.6%
FCF(TTM)1.36
FCFY9.27%
OCF(TTM)1.38
OCFY9.39%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)1.65
PEG (5Y)1.96
Graham Number11.27
Profitability
Industry RankSector Rank
ROA 8.73%
ROE 15.03%
ROCE 19.39%
ROIC 13.44%
ROICexc 18.99%
ROICexgc 105.66%
OM 8.52%
PM (TTM) 5%
GM 19.29%
FCFM 7.52%
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.7
Debt/EBITDA 0.17
Cap/Depr 6.62%
Cap/Sales 0.1%
Interest Coverage 21.13
Cash Conversion 76.34%
Profit Quality 150.51%
Current Ratio 2.06
Quick Ratio 1.35
Altman-Z 5.25
F-Score9
WACC7.33%
ROIC/WACC1.83
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y9.46%
EPS Next 2Y12.44%
EPS Next 3Y12.27%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year5.17%
Revenue Next 2Y6.28%
Revenue Next 3Y6.07%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year39.44%
EBIT Next 3Y18.54%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A

M1 KLINIKEN AG / M12.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?

ChartMill assigns a fundamental rating of 7 / 10 to M12.DE.


What is the valuation status for M12 stock?

ChartMill assigns a valuation rating of 5 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.


How profitable is M1 KLINIKEN AG (M12.DE) stock?

M1 KLINIKEN AG (M12.DE) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for M12 stock?

The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 15.6 and the Price/Book (PB) ratio is 2.44.


What is the financial health of M1 KLINIKEN AG (M12.DE) stock?

The financial health rating of M1 KLINIKEN AG (M12.DE) is 8 / 10.